Using AI and patient tissue to find treatments for ultra-rare cancers
SMARTCORE Technology: Using AI and Patient Tissue to Identify Potential Cancer Therapies for Ultra-rare Cancers
This study is testing a new way to use artificial intelligence to find existing drugs that could help treat a rare type of liver cancer called fibrolamellar cancer, making it easier for patients to get personalized treatment options based on their specific tumors.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10796286 on NIH RePORTER |
What this research studies
This research focuses on developing a novel approach called SmartCore, which utilizes artificial intelligence to screen primary human tumor tissues for potential cancer therapies. By analyzing intact tumors instead of traditional models, the project aims to identify existing drugs that could be repurposed for ultra-rare cancers, specifically targeting fibrolamellar cancer of the liver. The methodology involves using a machine-learning algorithm to predict how tumors respond to a wide range of drugs, thereby facilitating personalized treatment options. The goal is to bridge the gap between laboratory discoveries and clinical applications, making it easier to find effective therapies for patients with rare cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with ultra-rare cancers, particularly fibrolamellar cancer of the liver.
Not a fit: Patients with common cancers or those whose tumors cannot be analyzed using the SmartCore technology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide targeted and effective treatment options for patients suffering from ultra-rare cancers.
How similar studies have performed: While the approach is innovative, similar AI-driven drug screening methods have shown promise in other cancer types, suggesting potential for success in this novel application.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Gujral, Taran Singh — Fred Hutchinson Cancer Center
- Study coordinator: Gujral, Taran Singh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.